Candidate: COVID-19 XWG-03
Type: Recombinant protein-based vaccine combining Innovax’s XWG-03 vaccine technology and GSK’s pandemic adjuvant system, and based on multiple truncated S (spike) proteins.
Status: GSK disclosed in April it will make its pandemic adjuvant system available to Innovax to support preclinical evaluation of Innovax’s vaccine candidate against COVID-19, being developed with Xiamen University. Innovax plans to assess the S proteins to establish a lead candidate based on immunogenicity data. GSK and Innovax expanded a collaboration launched last year to develop a vaccine against human papillomavirus.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types:
● ANTIVIRAL
● VAX
● ANTIBODY
● RNA
